444 West Lake Street
Suite 1700
Chicago, IL 60606
United States
312 416 8592
https://www.MAIABiotech.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 13
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Vlad Vitoc M.B.A., M.D. | Co-Founder, President, CEO & Chairman of the Board of Directors | 529,82k | N/D | 1970 |
Mr. Jeffrey C. Himmelreich | Head of Finance | 213,17k | N/D | 1975 |
Dr. Sergei M. Gryaznov Ph.D. | Chief Scientific Officer | 417,33k | N/D | 1960 |
Linda Moreira | Company Secretary | N/D | N/D | N/D |
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
L'ISS Governance QualityScore di MAIA Biotechnology, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.